Canada markets closed

Filament Health Corp. (FH.NE)

Cboe CA - Cboe CA Real Time Price. Currency in CAD
Add to watchlist
0.0650-0.0050 (-7.14%)
At close: 02:10PM EST
Full screen
Previous Close0.0700
Open0.0700
Bid0.0650 x N/A
Ask0.0700 x N/A
Day's Range0.0650 - 0.0700
52 Week Range0.0550 - 0.2500
Volume34,000
Avg. Volume110,390
Market Cap13.177M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • News Direct

    Filament Health announces FDA opening of IND application for substance abuse disorder

    Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share the groundbreaking news that the U.S. Food and Drug Administration (FDA) has given its approval for the Investigationa...

  • CNW Group

    FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO ISRAEL

    Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has successfully completed an export of PEX010, the Company's botanical psilocybin drug candidate, to Israel. The shipment is believed to be the first botanical psilocybin to be exported to Israel. Hadassah University Hospital will study PEX010 in a clinical trial examining the effects of psilocybin for treatment-resist

  • CNW Group

    FILAMENT HEALTH ANNOUNCES FDA OPENING OF INVESTIGATIONAL NEW DRUG APPLICATION FOR SUBSTANCE USE DISORDERS

    Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PEX010, its botanical psilocybin drug candidate, for the treatment of Substance use Disorders (SUD).